Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

June 19, 2015

Join Kenneth Anderson, MD and Paul Richardson, MD as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.

The understanding of key pathways responsible for multiple myeloma  has led to the development of novel agents. This in turn has resulted in availability of many evidence-based options for treatment of MM contributing to significant improvements in response and survival.

Newly-diagnosed multiple myeloma is responsive to treatment with regimens containing immunomodulatory drugs (IMiDs) such as thalidomide and lenalidomide; proteasome inhibitors such as bortezomib; high-dose chemotherapy and autologous stem cell transplant in appropriate patients; or combinations containing melphalan and prednisone with novel agents.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with multiple myeloma
  • Describe the multidisciplinary aspects of the management of patients with multiple myeloma
  • Identify the key characteristics of multiple myeloma that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
06/18/2015
Course expires: 
08/12/2015
Event starts: 
06/19/2015 - 11:00am EDT
Event ends: 
06/19/2015 - 12:00pm EDT
Cost:
$0.00
Add to calendar: 

Kenneth Anderson, MD
Dana-Farber/Brigham and Women's Cancer Center

Paul Richardson, MD
Dana-Farber/Brigham and Women's Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing